Dog DNA test developer Embark Veterinary raised the capital in a round led by SoftBank Vision Fund 2 at a $700m post-money valuation.

Telecommunications and internet group SoftBank’s Vision Fund 2 led a $75m series B round yesterday for US-based canine DNA test provider Embark Veterinary.

Investment and financial services group Fidelity’s F-Prime Capital subsidiary also participated in the round, as did SV Angel, Slow Ventures, Freestyle Capital and Third Kind Venture Capital. It valued the company at $700m post-money, it told TechCrunch.

Embark is the creator of a DNA test capable of detecting more than 200 genetic health risks across some 350…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn